Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat

Endocrinology

Volumn 139, Issue 9, 1998, Pages 4012-4015

  Yamamoto, Michiko ^a   Murakami, Takehiko ^a   Nishikawa, Miyuki ^a   Tsuda, Eisuke ^b   Mochizuki, Shin Ichi ^b   Higashio, Kanji ^b   Akatsu, Takuhiko ^a   Motoyoshi, Kazuo ^a   Nagata, Naokazu ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b SNOW BRAND MILK PRODUCTS CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CELL SURVIVAL; CONTROLLED STUDY; HYPERCALCEMIA; HYPOCALCEMIA; MALE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; RAT; THYROPARATHYROIDECTOMY;

EID: 0031762476     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.139.9.6290     Document Type: Article

References (18)

1. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142
2. Yasuda H, Shima N, Nakagawa N, Mochizuki S, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337
3. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G Tarpley J, Derby P, Lee R, Amgen EST Program, Boyle WJ 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
4. Wisneski LA 1990 Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 46:S26-S30
5. Fleisch H 1991 Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcemic and metastatic bone disease. Drugs 42:919-944
6. Bilezikian JP 1992 Management of acute hypercalcemia. N Engl J Med 326:1196-1203
7. Engleman VW, Nickols GA, Ross FA, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL 1997 A peptidomimetic antagonist of the αvβ3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 99:2284-2292
8. Yamamoto M, Fisher JE, Gentile M, Seedor JG, Leu C-T, Rodan SB, Rodan GA 1998 The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology 139:1411-1419
9. Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M 1993 Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginylglycyl-aspartyl" (RGD)-containing protein. Endocrinology 132: 1411-1413
10. Masarachia P, Yamamoto M, Leu C-T, Rodan G, Duong L 1998 Histomorphometric evidence fof echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism. Endocrinology 139:1401-1410
11. Yamamoto M, Seedor JG, Rodan GA, Balena R 1995 Endogenous calcitonin attenuates parathyroid hormone-induced cancellous bone loss in the rats. Endocrinology 136:788-795
12. Parfitt AM 1987 Bone and plasma calcium homeostasis. Bone 8:S1-S8
13. Fisher JK, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M 1993 Response to letter. Endocrinology 133:2408-2409
14. Crippes BA, Engleman VW, Settle SL, Delarco J, Ornberg RL, Helfrich MH, Horton MA, Nickols GA 1996 Antibody to β3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology 137:918-924
15. Talmage RV, Munson PL, Lester GE, Boass A, Toverud SU, Hirsch PF 1993 Letter to the editor. Endocrinology 133:2407
16. Weinsbrode SE, Capen CC, Norman AW 1978 Ultrastructural evaluation of the effects of 1,25-dihydroxyvitamin D3 on bone of thyroparathyroidectomized rats fed a low-calcium diet. Am J Patho 92:459-465
17. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Sci USA 95:3597-3602
18. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhaub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176